Author:
Zhen Yong-zhan,Lin Ya-jun,Li Yi,Zhen Yong-su
Publisher
Springer Science and Business Media LLC
Subject
Pharmacology (medical),Pharmacology,General Medicine
Reference30 articles.
1. Gregory WM, Richards MA, Malpas JS . Combination chemotherapy versus melphalan and prednisolone in the treatment of multiple myeloma: an overview of published trials. J Clin Oncol 1992; 10: 334–42.
2. Chiusolo P, Sica S, Piccirillo N, Giordano G, Laurenti L, La Barbera EO, et al. Molecular and clinical follow-up after stem cell transplantation for multiple myeloma. Ann Hematol 2001; 80: 90–5.
3. Iguchi T, Yachide-Noguchi T, Hashimoto Y, Nakazato S, Sagawa M, Ikeda Y, et al. Novel tubulin-polymerization inhibitor derived from thalidomide directly induces apoptosis in human multiple myeloma cells: possible anti-myeloma mechanism of thalidomide. Int J Mol Med 2008; 21: 163–8.
4. Chauhan D, Hideshima T, Anderson KC . Targeting proteasomes as therapy in multiple myeloma. Adv Exp Med Biol 2008; 615: 251–60.
5. Pineda-Roman M, Zangari M, van Rhee F, Anaissie E, Szymonifka J, Hoering A, et al. VTD combination therapy with bortezomib- thalidomide-dexamethasone is highly effective in advanced and refractory multiple myeloma. Leukemia 2008; 22: 1419–27.
Cited by
13 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献